Figure 5
Figure 5. MM cells resistant to Akt inhibition can also be unresponsive to blockade of other survival pathways. (A) Western analysis of signaling pathway components in AMO-1 cells after knockdown of STAT3 and additional inhibition of the Ras/MAPK pathway with PD98059 (50 μM) and of Akt with Akti-1/2 (10 μM) (pSUPER = control vector, siSTAT3 = siRNA expression construct26). Transfected cells were purified 1 day after electroporation, cultured together with BMSCs, and treated with PD98059, Akti-1/2, or both. The next day, cells were harvested for Western blotting, and the same material was used to run 2 different gels to permit unequivocal staining of phosphorylated versus total protein. Only 1 of 2 identical tubulin controls is shown for clarity. (B) Viability of pSUPER-transfected AMO-1 cells after treatment with 10 μM Akti-1/2 and of siSTAT3-transfected cells additionally treated with 10 μM Akti-1/2 and 50 μM PD98059. Viability was assayed at day 5 of drug treatment; survival is calculated as the percentage of live cells compared with the pSUPER control sample. Cells were cocultured with BMSCs, and the graph displays the results from 3 independent experiments. Error bars mark standard deviations. (C) Signaling analysis of primary MM cells after treatment with Sant7 and PD98059. A total of 5 × 104 primary MM cells were kept in medium alone or in coculture with BMSCs for 24 hours. They were then treated overnight with Sant7 (50 μg/mL) or with an equivalent amount of buffer and changes in their phospho-STAT3 level were measured. Primary MM cells stimulated with 25 ng/mL IL-6 for 15 minutes served as positive control. Similarly, phospho-ERK1/2 signals were blocked with PD98059 (50 μM) and induced with PMA. (D) Viability of Akti-1/2–resistant/resilient primary MM cells (n = 7; individually coded) after additional blockade of the IL-6R/STAT3 and Ras/MAPK pathways. Freshly isolated MM cells were cocultured with BMSCs and incubated with Akti-1/2 (10 μM) or, in addition, with PD98059 (50 μM) and Sant7 (50 μg/mL). Viability was measured on day 5. Cells treated with DMSO served as control.

MM cells resistant to Akt inhibition can also be unresponsive to blockade of other survival pathways. (A) Western analysis of signaling pathway components in AMO-1 cells after knockdown of STAT3 and additional inhibition of the Ras/MAPK pathway with PD98059 (50 μM) and of Akt with Akti-1/2 (10 μM) (pSUPER = control vector, siSTAT3 = siRNA expression construct26 ). Transfected cells were purified 1 day after electroporation, cultured together with BMSCs, and treated with PD98059, Akti-1/2, or both. The next day, cells were harvested for Western blotting, and the same material was used to run 2 different gels to permit unequivocal staining of phosphorylated versus total protein. Only 1 of 2 identical tubulin controls is shown for clarity. (B) Viability of pSUPER-transfected AMO-1 cells after treatment with 10 μM Akti-1/2 and of siSTAT3-transfected cells additionally treated with 10 μM Akti-1/2 and 50 μM PD98059. Viability was assayed at day 5 of drug treatment; survival is calculated as the percentage of live cells compared with the pSUPER control sample. Cells were cocultured with BMSCs, and the graph displays the results from 3 independent experiments. Error bars mark standard deviations. (C) Signaling analysis of primary MM cells after treatment with Sant7 and PD98059. A total of 5 × 104 primary MM cells were kept in medium alone or in coculture with BMSCs for 24 hours. They were then treated overnight with Sant7 (50 μg/mL) or with an equivalent amount of buffer and changes in their phospho-STAT3 level were measured. Primary MM cells stimulated with 25 ng/mL IL-6 for 15 minutes served as positive control. Similarly, phospho-ERK1/2 signals were blocked with PD98059 (50 μM) and induced with PMA. (D) Viability of Akti-1/2–resistant/resilient primary MM cells (n = 7; individually coded) after additional blockade of the IL-6R/STAT3 and Ras/MAPK pathways. Freshly isolated MM cells were cocultured with BMSCs and incubated with Akti-1/2 (10 μM) or, in addition, with PD98059 (50 μM) and Sant7 (50 μg/mL). Viability was measured on day 5. Cells treated with DMSO served as control.

Close Modal

or Create an Account

Close Modal
Close Modal